Search research articles
Contact Us
Filters
Showing results (11-20 of 185) with videos related to
Page
of 19
Sort By:
Oncotarget
|
February 17, 2015
PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma
Jason J Luke, Patrick A Ott
Cancer
|
December 24, 2019
Considering adjuvant therapy for stage II melanoma
Andrew S Poklepovic, Jason J Luke
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 19, 2023
Myeloid Maturity: ATRA to Enhance Anti-PD-1?
Daniel J Olson, Jason J Luke
Pharmacological Research
|
March 22, 2017
Mechanistic and pharmacologic insights on immune checkpoint inhibitors
Randy F Sweis, Jason J Luke
Seminars in Oncology
|
April 10, 2012
Advances in the systemic treatment of cutaneous sarcomas
Jason J Luke, Mary Louise Keohan
Future Oncology (London, England)
|
May 11, 2022
A plain language summary from pembrolizumab plus ipilimumab following PD-1 antibody failure in melanoma
Daniel J Olson, Jason J Luke
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 25, 2023
CD16+ Macrophages: An Emerging Biomarker for Combined CTLA-4 and PD-1 Blockade
James W Smithy, Jason J Luke
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 15, 2024
NETosis Impact on Tumor Biology, Radiation, and Systemic Therapy Resistance
Yvonne M Mowery, Jason J Luke
Drug, Healthcare and Patient Safety
|
July 15, 2014
New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy
Jason J Luke, Patrick A Ott
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2025
And… We're Back: The Reemergence of CD137 in Cancer Immunotherapy via Antigen Anchoring
Matthew K Nguyen, Jason J Luke
Page
of 19
Search research articles
Search
Showing results (11-20 of 185) with videos related to
Sort By:
Page
of 19
Oncotarget
|
February 17, 2015
PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma
Jason J Luke, Patrick A Ott
Cancer
|
December 24, 2019
Considering adjuvant therapy for stage II melanoma
Andrew S Poklepovic, Jason J Luke
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 19, 2023
Myeloid Maturity: ATRA to Enhance Anti-PD-1?
Daniel J Olson, Jason J Luke
Pharmacological Research
|
March 22, 2017
Mechanistic and pharmacologic insights on immune checkpoint inhibitors
Randy F Sweis, Jason J Luke
Seminars in Oncology
|
April 10, 2012
Advances in the systemic treatment of cutaneous sarcomas
Jason J Luke, Mary Louise Keohan
Future Oncology (London, England)
|
May 11, 2022
A plain language summary from pembrolizumab plus ipilimumab following PD-1 antibody failure in melanoma
Daniel J Olson, Jason J Luke
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 25, 2023
CD16+ Macrophages: An Emerging Biomarker for Combined CTLA-4 and PD-1 Blockade
James W Smithy, Jason J Luke
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 15, 2024
NETosis Impact on Tumor Biology, Radiation, and Systemic Therapy Resistance
Yvonne M Mowery, Jason J Luke
Drug, Healthcare and Patient Safety
|
July 15, 2014
New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy
Jason J Luke, Patrick A Ott
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2025
And… We're Back: The Reemergence of CD137 in Cancer Immunotherapy via Antigen Anchoring
Matthew K Nguyen, Jason J Luke
Page
of 19